Network Version
LY341495 Data Sheet
| Product Name: | LY341495 |
 |
|---|---|---|
| CAS No.: | 201943-63-7 | |
| Cat. No.: | HY-70059 | |
| MWt: | 353.37 | |
| Formula: | C20H19NO5 | |
| Purity : | >98% | |
| Solubility: | DMSO : 6 mg/mL (16.98 mM; Need ultrasonic) | |
| Mechanisms: | Target: Neurological Disease | |
| Biological Activity: | ||
| LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively[5]. IC50 & Target: IC50: 2.9 nM (mGluR-2, human), 10 nM (mGluR-3, human), 170 nM (mGluR-8, human) In Vivo: LY341495 (0.3, 1, and 3 mg/kg, i.p.) displays a lower level of discrimination in rats[1]. LY341495 (3.0 mg/kg) decreases Dvl-2, pGSK-3α/β and β-catenin protein levels but Dvl-1, Dvl-3 and GSK-3α/β are unaffected in both the PFC and STR. LY341495 has the generally the opposite effect following acute and chronic administration compared to mGlu2/3 agonist, LY379268[2]. LY341495 (3 mg/kg, i.p., 2.5 h) -induced c-Fos expression is not altered in either KO brain. LY341495 is almost inactive in the central extended amygdala [central nucleus of the amygdala, lateral (CeL) and bed nucleus of the stria terminalis, laterodorsal (BSTLD)] in mGluR3-KO mice[3]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com